Table 2. Univariate analysis of baseline... | American Society of Hematology

Table 2.

Univariate analysis of baseline factors and the ASXL1 rs4911231 and BIM rs686952 variants in imatinib-treated patients

Factor	No. of patients	3-mo EMR		12-mo MMR		48-mo MR⁴		48-mo MR^4.5		48-mo FFS		48-mo progression to AP/BC		48-mo OS
Factor	No. of patients	3%	P	%	P	%	P	%	P	%	P	%	P	%	P
Overall response	528	77		48		50		31		74		4		95
Sokal risk group			<.0001		<.0001		.011		.005		<.0001		.259		.677
Low	215	87		56		55		37		83		2		96
Intermediate	161	74		47		50		32		72		6		94
High	130	65		38		43		20		59		6		94
Sex			.12		.026		.009		.074		.311		.210		.058
Female	225	77		57		56		34		75		3		97
Male	303	77		42		46		28		71		5		93
BCR-ABL1 transcript type			.212		.701		.068		.018		.0741		.782		.393
e13a2	198	79		43		47		25		78		4		96
e14a2	229	76		54		54		38		73		3		95
e13a2 and e14a2	96	77		45		54		25		65		6		92
Median age, y			.43		.24		.38		.12		.672		.520		.523
≤48	269	77		46		49		27		73		5		95
>48	259	77		51		51		34		73		3		94
Imatinib starting dose, mg			.005		.682		.088		.264		.054		.797		.164
400	90	67		43		50		24		71		2		98
600	313	80		49		55		34		75		4		92
800	125	79		51		40		29		71		5		96
ASXL1 rs4911231 genotype			.029		.012		.013		<.0001		.002		.200		.622
Good risk	155	85		56		59		43		83		2		96
Poor risk	353	75		46		47		26		71		4		94
BIM rs686952 genotype			.002		<.0001		<.0001		<.0001		.035		.057		.347
Good risk	249	84		55		60		41		80		2		96
Poor risk	259	73		44		43		22		70		5		93

Factor	No. of patients	3-mo EMR		12-mo MMR		48-mo MR⁴		48-mo MR^4.5		48-mo FFS		48-mo progression to AP/BC		48-mo OS
Factor	No. of patients	3%	P	%	P	%	P	%	P	%	P	%	P	%	P
Overall response	528	77		48		50		31		74		4		95
Sokal risk group			<.0001		<.0001		.011		.005		<.0001		.259		.677
Low	215	87		56		55		37		83		2		96
Intermediate	161	74		47		50		32		72		6		94
High	130	65		38		43		20		59		6		94
Sex			.12		.026		.009		.074		.311		.210		.058
Female	225	77		57		56		34		75		3		97
Male	303	77		42		46		28		71		5		93
BCR-ABL1 transcript type			.212		.701		.068		.018		.0741		.782		.393
e13a2	198	79		43		47		25		78		4		96
e14a2	229	76		54		54		38		73		3		95
e13a2 and e14a2	96	77		45		54		25		65		6		92
Median age, y			.43		.24		.38		.12		.672		.520		.523
≤48	269	77		46		49		27		73		5		95
>48	259	77		51		51		34		73		3		94
Imatinib starting dose, mg			.005		.682		.088		.264		.054		.797		.164
400	90	67		43		50		24		71		2		98
600	313	80		49		55		34		75		4		92
800	125	79		51		40		29		71		5		96
ASXL1 rs4911231 genotype			.029		.012		.013		<.0001		.002		.200		.622
Good risk	155	85		56		59		43		83		2		96
Poor risk	353	75		46		47		26		71		4		94
BIM rs686952 genotype			.002		<.0001		<.0001		<.0001		.035		.057		.347
Good risk	249	84		55		60		41		80		2		96
Poor risk	259	73		44		43		22		70		5		93